Phase II of Lenvatinib Plus Toripalimab for Advanced HCC
Status:
Withdrawn
Trial end date:
2019-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of lenvatinib combined with
toripalimab in patients with advanced hepatocellular carcinoma (HCC)